Evidence map›Paper›PMID 37258998›Full record

ReviewArchivum immunologiae et therapiae experimentalis2023

The Pyroptotic and Nonpyroptotic Roles of Gasdermins in Modulating Cancer Progression and Their Perspectives on Cancer Therapeutics.

Sheng-Kai Hsu, Yi-En Chen, En-De Shu, Ching-Chung Ko, Wen-Tsan Chang, I-Ling Lin, Chia-Yang Li, Rovelyn P Gallego, Chien-Chih Chiu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archivum immunologiae et therapiae experimentalis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sheng-Kai HsuDepartment of Biotechnology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Yi-En ChenDepartment of Biotechnology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
En-De ShuDepartment of Biotechnology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Ching-Chung KoDepartment of Medical Imaging, Chi Mei Medical Center, Tainan, 710, Taiwan.
Wen-Tsan ChangDivision of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan.
I-Ling LinDepartment of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Chia-Yang LiGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Rovelyn P GallegoDepartment of Biomedical Science and Environment Biology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Chien-Chih ChiuDepartment of Biotechnology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. cchiu@kmu.edu.tw.ORCID http://orcid.org/0000-0001-7307-2468
Kaohsiung Medical University · TWChi Mei Medical Center · TWNational Sun Yat-sen University · TW

Funding

Kaohsiung Medical University KMU-M111024Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH110-0M40Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH 111-1R35National Science and Technology Council (TW) MOST 109-2314-B-037-069-MY3NSYSU-KMU joint grants NSYSUKMU112-P23NSYSU-KMU joint grants NSYSUKMU112-P24
6 · The paper itself

Abstract

Gasdermins (GSDMs) are a protein family encoded by six paralogous genes in humans, including GSDMA, GSDMB, GSDMC, GSDMD, GSDME (also known as DFNA5), and DFNB59 (also known as pejvakin). Structurally, members of the GSDM family possess a C-terminus (an autoinhibitory domain) and a positively charged N-terminus (a pore-forming domain) linked with divergent peptide linkers. Recently, GSDMs have been identified as key executors of pyroptosis (an immunogenic programmed cell death) due to their pore-forming activities on the plasma membrane when proteolytically cleaved by caspases or serine proteases. Accumulating studies suggest that chemoresistance is attributed to dysregulation of apoptotic machinery and that inducing pyroptosis to bypass aberrant apoptosis can potently resensitize apoptosis-resistant cancer to chemotherapeutics. Pyroptosis is initiated by pore formation and culminates with plasma membrane rupture; these processes enable the release of proinflammatory cytokines (e.g., IL-1β and IL-18) and damage-associated molecular patterns, which further modulate antitumor immunity within the tumor microenvironment. Although pyroptosis is considered a promising strategy to boost antitumor effects, it is also reported to cause unwanted tissue damage (e.g., gut damage and nephrotoxicity). Intriguingly, mounting evidence has uncovered nonpyroptotic roles of GSDMs in tumorigenesis, such as proliferation, invasion, metastasis, and drug resistance. Thus, this provides a rationale for GSDMs as potential therapeutic targets. Taken together, we shed unbiased light on the pyroptosis-dependent roles of GSDMs in cancer progression and highlighted how GSDMs modulate tumorigenesis in a pyroptosis-independent manner. It is evident that targeting GSDMs seems profound in cancer management; however, several problems require further investigation to target GSDMs from bench to bedside, which is elucidated in the discussion section.

Indexed as

GasderminsNeoplasmsApoptosisBiomarkers, TumorCarcinogenesisHumansInflammasomesNeoplasm ProteinsPore Forming Cytotoxic ProteinsTumor MicroenvironmentBiomarkers, TumorGasderminsGSDMA protein, humanGSDMC protein, humanInflammasomesNeoplasm ProteinsPore Forming Cytotoxic ProteinsAntitumor immunityChemosensitivityGasderminsNonpyroptosisPyroptosis

Identifiers

PMID37258998
OpenAlexW4378805597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.